BioSpace News Archive

Otonomy, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, announced that management is scheduled to participate in two upcoming virtual conferences

Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced that the American Academy of Orthopaedic Surgeons (AAOS) included ZILRETTA (triamcinolone acetonide extended-release injectable suspension) in its updated evidence-based clinical practice guidelines for the management of osteoarthritis (OA) of the knee.

Cabaletta Bio, Inc., a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, announced that the Company will participate in two upcoming investor conferences in September:

PMV Pharmaceuticals, Inc., a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants, announced that David H. Mack, Ph.D., President & Chief Executive Officer, will present at the Morgan Stanley 19th Annual Global Healthcare Conference taking place September 9-10 and 13-15, 2021.

Jounce Therapeutics, Inc., a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, announced that company management will participate at several upcoming investor conferences in September:

Avadel Pharmaceuticals plc, a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in adults with narcolepsy, announced that Greg Divis, Chief Executive Officer of Avadel, will participate in the following upcoming virtual investor conferences in September:

Global Blood Therapeutics, Inc. announced that it will participate in virtual fireside chats at the following investor conferences.

Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), today announced that the first patient has been dosed in a China specific pivotal trial evaluating CBP-201 in adults with moderate-to-severe atopic dermatitis.

Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Morgan Stanley 19th Annual Global Healthcare Conference.

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced a $192.5 million contract award from the U.S. Department of Defense (DoD) to ensure reliable domestic production of pipette tips, which are used within research and diagnostic labs to dispense precise amounts of liquid